ATE331798T1 - Verfahren zur anregung einer immunantwort durch verabreichung von nutzorganismen, die intimin allein oder als fusionsprotein mit einem oder mehreren anderen antigenen exprimieren - Google Patents

Verfahren zur anregung einer immunantwort durch verabreichung von nutzorganismen, die intimin allein oder als fusionsprotein mit einem oder mehreren anderen antigenen exprimieren

Info

Publication number
ATE331798T1
ATE331798T1 AT97918538T AT97918538T ATE331798T1 AT E331798 T1 ATE331798 T1 AT E331798T1 AT 97918538 T AT97918538 T AT 97918538T AT 97918538 T AT97918538 T AT 97918538T AT E331798 T1 ATE331798 T1 AT E331798T1
Authority
AT
Austria
Prior art keywords
intimately
antigens
stimulating
express
administration
Prior art date
Application number
AT97918538T
Other languages
English (en)
Inventor
Charles N Stewart
Marian L Mckee
Alison D O'brien
Marian R Dr Wachtel
Original Assignee
Jackson H M Found Military Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jackson H M Found Military Med filed Critical Jackson H M Found Military Med
Application granted granted Critical
Publication of ATE331798T1 publication Critical patent/ATE331798T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97918538T 1996-04-19 1997-04-18 Verfahren zur anregung einer immunantwort durch verabreichung von nutzorganismen, die intimin allein oder als fusionsprotein mit einem oder mehreren anderen antigenen exprimieren ATE331798T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1565796P 1996-04-19 1996-04-19
US1593896P 1996-04-22 1996-04-22

Publications (1)

Publication Number Publication Date
ATE331798T1 true ATE331798T1 (de) 2006-07-15

Family

ID=26687661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97918538T ATE331798T1 (de) 1996-04-19 1997-04-18 Verfahren zur anregung einer immunantwort durch verabreichung von nutzorganismen, die intimin allein oder als fusionsprotein mit einem oder mehreren anderen antigenen exprimieren

Country Status (9)

Country Link
US (3) US6261561B1 (de)
EP (1) EP0895543B1 (de)
JP (2) JP2000510332A (de)
AR (1) AR006718A1 (de)
AT (1) ATE331798T1 (de)
AU (1) AU722327B2 (de)
CA (1) CA2252439C (de)
DE (1) DE69736226T2 (de)
WO (1) WO1997040177A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
WO1997040161A1 (en) * 1996-04-19 1997-10-30 Henry M. Jackson Foundation For The Advancement Of Military Medecine Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
GB9803322D0 (en) * 1998-02-16 1998-04-15 Imperial College Methods
AU1199900A (en) * 1998-09-30 2000-04-17 Walter Reed Army Institute Of Research Use of purified invaplex from gram negative bacteria as a vaccine
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
US6703492B1 (en) * 1999-11-09 2004-03-09 Smithkline Beecham Corporation Staphylococcus epidermidis nucleic acids and proteins
DE10053224A1 (de) * 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
US7276605B2 (en) * 2001-02-01 2007-10-02 Roche Diagnostics Operations, Inc. Method for producing recombinant trypsin
WO2002079240A2 (en) * 2001-03-29 2002-10-10 Imperial College Innovations Limited Intimins for the prevention or treatment of infections: i
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US6841349B2 (en) * 2001-05-07 2005-01-11 Applera Corporation Applied Biosystems Group Methods for the reduction of stutter in microsatellite amplification
JP4283666B2 (ja) * 2001-06-21 2009-06-24 クローンテック ラボラトリーズ インク． 水溶性ポリマー金属イオンアフィニティ組成物、およびその使用方法
KR100471116B1 (ko) * 2001-12-12 2005-03-08 주식회사 단바이오텍 장독성 대장균 감염의 예방 및 치료에 유용한 수용성단백질 및 이를 포함한 알 및 이들의 제조 방법
WO2003053461A2 (en) * 2001-12-21 2003-07-03 Societe Des Produits Nestle S.A. Lactic acid bacteria for preventing infection with intimin expressing pathogens
KR100471114B1 (ko) * 2001-12-26 2005-03-08 주식회사 단바이오텍 장출혈성 대장균 감염의 예방 및 치료를 위한 항체, 이를포함하는 알 및 이들의 제조방법
AU2003250250B2 (en) * 2002-06-19 2008-02-14 Intrexon Actobiotics Nv Methods and means to promote gut absorption
EP1560935A2 (de) * 2002-11-15 2005-08-10 VIB vzw Selbst-enthaldender lactobacillus strain
US7344718B2 (en) * 2003-01-31 2008-03-18 University Of North Dakota Yersinia species compositions
US20050158329A1 (en) * 2004-01-21 2005-07-21 Ghosh Swapan K. Novel phytol derived immunoadjuvants and their use in vaccine formulations
WO2005115130A2 (en) * 2004-05-24 2005-12-08 The State Of Israel - Ministry Of Agriculture & Rural Development, Agricultural Research Organization Transgenic ficus, method for producing same and use thereof
US7294614B2 (en) * 2004-10-12 2007-11-13 Clontech Laboratories, Inc. Phosphoprotein affinity resins and methods for making and using the same
EP1824971B1 (de) * 2004-11-22 2016-01-13 New York University Genetisch veränderte clostridiengene, durch die veränderten gene kodierte proteine und deren verwendungen
JP5410759B2 (ja) 2005-11-29 2014-02-05 アクトジェニックス・エヌブイ 抗原に対する粘膜寛容の誘導
EP2125010B1 (de) 2007-01-25 2014-06-04 Actogenix N.V. Behandlung von immunkrankheiten durch mukosale abgabe von antigenen mit genetisch modifiziertem lactobacillus
MX2010011938A (es) 2008-05-02 2010-12-01 Idemitsu Kosan Co Vacuna para toxina bacteriana.
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
WO2011123495A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
US9211327B2 (en) 2011-06-22 2015-12-15 University Of North Dakota Use of YSCF, truncated YSCF and YSCF homologs as adjuvants
US10131695B2 (en) 2011-09-20 2018-11-20 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
CA2895508A1 (en) 2012-12-18 2014-06-26 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
WO2014117148A1 (en) 2013-01-28 2014-07-31 New York University Treatment methods using atoxic neurotoxin derivatives
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US11897921B2 (en) 2014-12-09 2024-02-13 New York University Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380831A (en) 1986-04-04 1995-01-10 Mycogen Plant Science, Inc. Synthetic insecticidal crystal protein gene
US4736017A (en) 1984-04-30 1988-04-05 The Board Of Trustees Of The Leland Stanford Junior University Chemically defined vaccine against urinary infections
US4740585A (en) 1984-07-30 1988-04-26 The Board Of Trustees Of The Leland Stanford Junior University Synthetic vaccine against urinary infections
IL78775A (en) 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
US5378824A (en) 1986-08-26 1995-01-03 E. I. Du Pont De Nemours And Company Nucleic acid fragment encoding herbicide resistant plant acetolactate synthase
US5049500A (en) 1987-01-13 1991-09-17 E. I. Du Pont De Nemours Pollen-mediated gene transformation in plants
CA1340522C (en) 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
WO1990002484A1 (en) 1988-09-06 1990-03-22 Washington University Oral immunization by transgenic plants
US5168063A (en) 1990-07-27 1992-12-01 Wisconsin Alumni Research Foundation Monoclonal antibody to enterohemorrhagic escherichia coli 0157:h7 and 026:h11
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US5484719A (en) * 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
CA2078716A1 (en) * 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
EP0708656B1 (de) * 1993-04-27 2002-07-31 United Biomedical, Inc. Immunogene lhrh peptidkonstrukion und synthetische, universale immunstimulatoren als impfstoffe
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
ES2164759T3 (es) 1993-12-09 2002-03-01 Texas A & M Univ Sys Transformacion de especies musa utilizando agrobacterium tumefaciens.
AU2816095A (en) * 1994-06-24 1996-01-19 Children's Hospital Medical Center Escherichia coli o157:h7 epithelial adhesin
WO1996012801A1 (en) 1994-10-24 1996-05-02 The Texas A & M University System Oral immunization with transgenic plants
US5747293A (en) * 1995-03-23 1998-05-05 Imperial College Of Science, Technology & Medicine Intimin-like proteins of E. coli

Also Published As

Publication number Publication date
CA2252439A1 (en) 1997-10-30
DE69736226D1 (de) 2006-08-10
WO1997040177A1 (en) 1997-10-30
EP0895543A1 (de) 1999-02-10
AU2662197A (en) 1997-11-12
AR006718A1 (es) 1999-09-08
US6881411B2 (en) 2005-04-19
CA2252439C (en) 2014-09-30
EP0895543B1 (de) 2006-06-28
JP2000510332A (ja) 2000-08-15
DE69736226T2 (de) 2006-11-09
US6261561B1 (en) 2001-07-17
AU722327B2 (en) 2000-07-27
US20030147902A1 (en) 2003-08-07
US6406885B1 (en) 2002-06-18
JP2008161199A (ja) 2008-07-17

Similar Documents

Publication Publication Date Title
ATE331798T1 (de) Verfahren zur anregung einer immunantwort durch verabreichung von nutzorganismen, die intimin allein oder als fusionsprotein mit einem oder mehreren anderen antigenen exprimieren
DE3684035D1 (de) Verfahren zur herstellung polymere mikroteilchen mit pestizider wirksamkeit.
DE68901541D1 (de) Verfahren zur herstellung von fluor enthaltenden olefinen.
DE3684426D1 (de) Verfahren zur herstellung von photochromen gegenstaenden.
DE68903482D1 (de) Zement, verfahren zur herstellung dieses zements und verfahren zur herstellung von produkten mit diesem zement.
DE3671858D1 (de) Verfahren zur herstellung von verbundplatten.
DE3382190D1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
DE68902700D1 (de) Verfahren zur herstellung von synthetischem schmieroel durch olefinoligomerisation.
DE3582870D1 (de) Verfahren zur herstellung von deuteriertem methylacrylat oder methylmethacrylat.
DE68909528D1 (de) Verfahren zur herstellung von methacrylsaeure.
DE3585052D1 (de) Verfahren zur herstellung von l-isoleucin durch fermentation.
DE3677518D1 (de) Verfahren zur herstellung von vinylpolymeren.
DE3863780D1 (de) Verfahren zur herstellung von teilchen mit monodisperser teilchengroesse.
ATA80383A (de) Verfahren zur herstellung von tert. butylalkylaethern in gegenwart von butadien
DE69331269D1 (de) Verfahren zur herstellung von antikörpern
DE3860768D1 (de) Verfahren zur herstellung von hochduktilem tantal-halbzeug.
DE3874857D1 (de) Verfahren zur herstellung eines mit pfropfung modifizierten alpha-olefin-copolymers.
DE3864713D1 (de) Verfahren zur herstellung von ibuprofen.
ATA210888A (de) Verfahren zur herstellung von fluessigkeitsabsorbierenden acrylharzen
DE3763186D1 (de) Verfahren zur umstrukturierung von olefinen.
DE58904259D1 (de) Verfahren zur hydrierung von alfa, beta-ungesaettigten ketonen.
DE58902137D1 (de) Verfahren zur herstellung von caprolacton.
DE58905117D1 (de) Verfahren zur herstellung von 4-chlor-2,5-dimethoxyanilin.
DE3867963D1 (de) Verfahren zur fertigung von gummi-laminaten.
DE68924646D1 (de) Verfahren zur herstellung von zinkoxid-whiskern.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties